Two Seas Capital LP boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,167,807 shares of the company's stock after purchasing an additional 442,914 shares during the period. Roivant Sciences makes up approximately 9.5% of Two Seas Capital LP's investment portfolio, making the stock its 3rd biggest holding. Two Seas Capital LP owned approximately 1.40% of Roivant Sciences worth $120,285,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in shares of Roivant Sciences in the 4th quarter valued at approximately $39,000. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after buying an additional 3,426 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Insider Transactions at Roivant Sciences
In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the sale, the chief operating officer now directly owns 1,116,345 shares of the company's stock, valued at approximately $11,409,045.90. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock valued at $14,922,538 in the last ninety days. 7.90% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several research firms recently issued reports on ROIV. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Check Out Our Latest Report on ROIV
Roivant Sciences Stock Up 1.6 %
Shares of ROIV stock traded up $0.18 on Monday, hitting $11.19. The company had a trading volume of 8,301,459 shares, compared to its average volume of 5,473,407. The company has a 50-day moving average price of $10.34 and a 200-day moving average price of $11.14. The firm has a market cap of $7.98 billion, a P/E ratio of -74.60 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
